Publications by authors named "S Sezgin Goksu"
Introduction: Despite the rapid evolution in management of metastatic renal cell carcinoma (mRCC) over the past decade, challenges remain in accessing new therapies in some parts of the world. Despite therapeutic advancements, attrition rates remain persistently high. This study aims to assess the treatment patterns and attrition rates of patients with mRCC in oncology clinics across Turkey.
View Article and Find Full Text PDFBackground And Aims: During liver transplantation, hepatocellular carcinoma (HCC) recurrence remains a critical challenge for patient survival. Targeted therapies, such as sorafenib and regorafenib, have been utilized to manage relapsed HCC in this unique setting. This study aimed to assess the efficacy of Sorafenib and Regorafenib in patients with HCC who experienced recurrence after liver transplantation.
View Article and Find Full Text PDFObjective: We aimed to predict the risk of hypotension due to spinal anesthesia (HSA) by measuring the diameter and area of the inferior vena cava (IVC-D, IVC-A) through ultrasound and pleth variability index (PVI) in patients who underwent endovenous radiofrequency ablation under spinal anesthesia (SA).
Methods: This cross-sectional, observational, and prospective study was completed with 64 patients. Before SA, PVI IVC-D, and IVC-A were measured.
Lung cancer is the leading cause of cancer-related death globally and is often diagnosed at an advanced stage. Nivolumab represents a significant advancement for treating advanced non-small cell lung cancer (NSCLC). However, the absence of reliable biomarkers predicting treatment response hinders personalized therapy.
View Article and Find Full Text PDFArticle Synopsis
- Simlukafusp alfa (FAP-IL2v) is an engineered immune cytokine aimed at enhancing immune responses specifically in tumor environments, and was evaluated with atezolizumab for treating recurrent/metastatic cervical squamous cell carcinoma (SCC) in a phase 2 study.
- A total of 48 patients with advanced cervical SCC who had previously received treatment were enrolled; the study primarily measured the objective response rate, yielding a 27% response with a median duration of 13.3 months for those who responded.
- The combination treatment showed clinical efficacy with manageable side effects, including immune cell activation, indicating a promising approach for this patient group.